Persephoni

What Persephoni does

Persephoni BioPartners (legal entity: Persephoni Biosciences LLC) is a privately held life sciences venture studio founded in 2024 and headquartered in Durham, North Carolina. The company builds biotech ventures by sourcing breakthrough science from academic institutions and founder-led teams, then providing company formation, operational infrastructure, regulatory strategy, and capital deployment through its proprietary "Persephoni Breakthrough System" framework. As of mid-2025, Persephoni has launched four portfolio companies spanning distinct therapeutic modalities: LampRNA Therapeutics (lysosome-mediated RNA degrader platform for RNAi therapeutics), Telos Therapeutics (exosome-based therapies for autoimmunity and oncology), InnoVira Therapeutics (EBV-specific antivirals targeting MS and EBV-associated diseases), and Monarch Therapeutics (universal CAR adaptor platform for T-cell therapies against solid tumors).

Persephoni's go-to-market is a hybrid private-equity / venture-studio model. It generates returns primarily through equity ownership in portfolio companies, supplemented by management fees and future carried interest from its capital vehicles. The company has established Persephoni BioVentures, a dual-platform investment initiative comprising an Evergreen Non-Profit Fund and a targeted $100M+ Global Venture Fund, alongside the Clinical Impact Studio in Research Triangle Park — a global platform developed in partnership with the American Cancer Society's BrightEdge to accelerate oncology translational research into clinical-stage drug candidates. Strategic partnerships with LOUD Ventures, o2h ventures, and Nucleate Bio extend deal flow, and the firm engages founders through a website application portal plus direct outreach.

The leadership team is the company's primary operating asset. CEO and founder Hilary Schultz previously scaled Nucleate Bio's Organizational Development Initiative to 18 regions and 101 companies formed. CSO William Heath is a 36-year pharmaceutical veteran and former Group VP at Eli Lilly; the C-suite additionally draws from Chroma Medicine, Vor Biopharma, bluebirdbio, AbbVie, FDA, REGENXBIO, Lonza, Guggenheim Partners, and McKinsey. Advisors include former Medtronic Chairman and CEO William A. Hawkins. The studio claims a team-level track record of 300+ therapies advanced to clinic, 25+ FDA approvals, and $30B+ in deal-sheet value, with management citing the conversion of $1.5M in founder capital into $51M in enterprise value across four startups in under six months as evidence of capital efficiency.

Name

Persephoni

Legal name

Persephoni Biosciences LLC

Website

https://persephonibio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Spring Lake

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Venture Studio / Company Building: Persephoni operates as a hybrid private equity and venture model. They create and scale biotech companies through their venture studio approach, generating returns through equity ownership in portfolio companies they help form and grow.
2. Strategic Partnerships and Sponsorships: Revenue generated through strategic partnerships including sponsorships (e.g., $1.5M sponsorship to ACS BrightEdge) and collaboration agreements with pharmaceutical companies, investors, and ecosystem partners.
3. Capital Deployment: The company raises and deploys capital through venture funds (e.g., $100M+ Global Venture Fund) and manages capital structures for portfolio companies, generating management fees and carry.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Persephoni builds and operates biotech companies by partnering with academic inventors and scientific founders at the earliest stages of company formation. It provides end-to-end company-building services — formation, operational support, regulatory and clinical strategy, partnership facilitation, and capital deployment through its Breakthrough System framework — while taking equity ownership in the portfolio companies it creates (LampRNA Therapeutics, Telos Therapeutics, InnoVira, Monarch Therapeutics) and managing targeted investment funds including a $100M+ Global Venture Fund.

Product overview

Persephoni BioPartners is a global venture creation and development firm (venture studio) focused on launching and scaling transformational biotech companies. The company operates through its Clinical Impact Studio and manages a portfolio of four distinct portfolio companies: LampRNA Therapeutics (lysosome-mediated RNA degrader platform for enhanced RNAi therapies), Telos Therapeutics (exosome-based therapies for autoimmunity and oncology), InnoVira (EBV-specific antivirals targeting MS and EBV-associated conditions), and Monarch Therapeutics (Universal CAR Adaptor platform for T-cell therapies). The Persephoni Breakthrough System provides a repeatable framework to advance discoveries from research to therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• LampRNA Therapeutics Persephoni portfolio company that has developed the world's first lysosome-mediated RNA degrader platform combining lysosomal and enzyme-mediated degradation pathways to transform ASOs and siRNAs into potent gene silencers, offering enhanced knockdown, reduced dosing, and better safety profiles for RNA interfering therapies.
• Telos Therapeutics Persephoni portfolio company developing highly potent exosome-based therapies for Autoimmunity and Oncology, using a universal base exosome platform with multiple biological effectors on the surface.
• InnoVira Therapeutics Corporation Persephoni portfolio company developing the world's first EBV-specific antiviral medication using small-molecule compounds that disrupt viral machinery to target the root cause of MS and other EBV-associated conditions including cancer and mononucleosis.
• Monarch Therapeutics Persephoni portfolio company developing a Universal CAR Adaptor receptor platform that guides T-Cell therapies against any cancer using tagged targeting molecules, enabling engineer-once, treat-infinitely personalized precision medicine for solid tumor malignancies.
• Clinical Impact Studio Global platform based in Research Triangle, North Carolina that bridges early-stage scientific breakthroughs with the clinical development and investment support required to advance them into and through the clinical development journey; functions as a hub for company formation, strategic guidance, and targeted capital deployment into high-potential oncology startups.

Quantifiable outcome

• $1.5M founder capital transformed into $51M enterprise value across four biotech startups in under six months
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered core.

• ACS BrightEdgecoreStrategic or Co-development Partner · 3 September 2025Strategic partnership with American Cancer Society's BrightEdge innovation and impact investment arm. Persephoni announced a $1.5 million sponsorship to accelerate translational oncology research into clinical-stage drug candidates. The partnership will develop the Clinical Impact Studio, leveraging ACS BrightEdge's deep research network and impact investment infrastructure with Persephoni's translational and company-building capabilities. Persephoni will collaborate with BrightEdge leadership to identify promising oncology innovations from ACS grantees and entrepreneurs.
• LOUD VenturescoreStrategic or Co-development Partner · 1 April 2025LOUD Ventures and Persephoni Bio announced a strategic partnership to support biotech innovation and company formation. The partnership combines LOUD Ventures' investment capabilities with Persephoni's venture studio model and company-building expertise.
• o2h venturescoreStrategic or Co-development PartnerStrategic partnership with o2h ventures focused on biotech discovery and company formation. o2h discovery is part of the o2h group with expertise in biotech innovation. Persephoni portfolio company InnoVira participated in the o2h Discovery Kickstarter program, accelerating its medicinal chemistry program.
• Nucleate BiocoreStrategic or Co-development PartnerPersephoni partners with Nucleate Bio, the largest global community of bio-innovators. CEO Hilary Schultz previously founded the Organizational Development Initiative at Nucleate Bio, scaling it to 18 regions worldwide with 50+ programs and 101 companies formed. Persephoni continues to engage with the Nucleate ecosystem for deal flow and founder relationships.
• Academic InstitutionscoreStrategic or Co-development PartnerPersephoni partners with academic institutions to turn breakthrough science into real-world impact. Working with R1 research universities and technology transfer offices to identify promising discoveries and support company formation from academic research.
• o2h discoverycoreStrategic or Co-development PartnerPersephoni Bio collaboration with o2h discovery through their kickstarter program. InnoVira, a Persephoni portfolio company, is a recipient of the o2h Discovery Kickstarter program, which has allowed rapid acceleration of medicinal chemistry programs to generate lead candidates faster.
• NucleatecoreStrategic or Co-development PartnerPersephoni leadership (Hilary Schulz and William Heath) appeared on the Nucleate Podcast discussing science to startup topics and real talk on biotech founding. Nucleate is a global movement and the largest global community of bio-innovators.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ARCH Venture Partners: ARCH Venture Partners is a long-tenured biotech venture creation firm that co-founds and builds companies out of breakthrough science, often in deep tech and platform modalities. Its venture studio-style origination is directly comparable to Persephoni's approach.
• Flagship Pioneering: Flagship Pioneering is the prototypical biotech venture studio, originating companies such as Moderna through a model of creating and incubating breakthrough science ventures. Like Persephoni, Flagship combines scientific translation, company formation, and ongoing capital support across a portfolio of platform-driven biotechs.
• Versant Ventures: Versant Ventures is a healthcare-focused venture firm that builds biotech companies, often with operational involvement, around novel science. Its combination of early-stage company creation and ongoing operating support matches Persephoni's venture studio model.
• RA Capital Management: RA Capital is a healthcare-focused investment firm that supports biotech companies from formation through commercialization. Its deep operational involvement and biotech-only mandate are comparable to Persephoni's venture studio focus.
• Atlas Venture: Atlas Venture is a biotech-focused venture firm that actively creates, seeds, and builds therapeutic companies from academic science. The venture-creation and operations support parallels Persephoni's Clinical Impact Studio and Breakthrough System model.
• Apple Tree Partners: Apple Tree Partners operates a hybrid venture creation and investment platform focused on forming and scaling biotech companies through operational expertise. Like Persephoni, it pairs in-house operating partners with scientific founders.
• 5AM Ventures: 5AM Ventures is an early-stage biotech venture firm that partners with academic founders to translate scientific discoveries into therapeutic companies. Its founder-centric, science-driven origination is directly comparable to Persephoni's model.
• Accelerator Life Science Partners: Accelerator Life Science Partners is a biotech venture creation firm that launches and operates companies around academic discoveries through an in-house operationally led model. Its company-building framework is highly comparable to Persephoni's Breakthrough System.
• Frazier Life Sciences: Frazier Life Sciences invests in and builds biotech companies with significant operational involvement, often in partnership with scientific founders. Its active company-creation stance aligns with Persephoni's hands-on, equity-aligned venture studio model.
• Third Rock Ventures: Third Rock Ventures builds biotech companies from scientific breakthroughs, focusing on company formation around novel platforms and bringing in operational leaders. The model closely matches Persephoni's approach of pairing operational expertise with founders to translate academic science into biotech companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/persephoni-biopartners

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Persephoni